258 related articles for article (PubMed ID: 29742974)
21. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
22. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic
Tahara M; Kiyota N; Imai H; Takahashi S; Nishiyama A; Tamura S; Shimizu Y; Kadowaki S; Ito KI; Toyoshima M; Hirashima Y; Ueno S; Sugitani I
Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359
[No Abstract] [Full Text] [Related]
23. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
[No Abstract] [Full Text] [Related]
24. Detection of BRAFV600E by digital PCR on fine-needle aspirate enables rapid initiation of dabrafenib and trametinib in unresectable anaplastic thyroid carcinoma.
Buffet C; Allard L; Guillerm E; Ghander C; Mathy E; Lussey-Lepoutre C; Julien N; Touma E; Quilhot P; Godiris-Petit G; Lacorte JM; Leenhardt L; Denis JA
Eur J Endocrinol; 2022 Sep; 187(3):K33-K38. PubMed ID: 35900324
[TBL] [Abstract][Full Text] [Related]
25. BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.
Lim AM; Taylor GR; Fellowes A; Cameron L; Lee B; Hicks RJ; McArthur GA; Angel C; Solomon B; Rischin D
J Natl Compr Canc Netw; 2016 Mar; 14(3):249-54. PubMed ID: 26957611
[TBL] [Abstract][Full Text] [Related]
26. Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.
da Silva TN; Rodrigues R; Saramago A; Pires C; Rito M; Horta M; Martins C; Leite V; Cavaco BM
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651156
[TBL] [Abstract][Full Text] [Related]
27. [Anaplastic thyroid carcinoma : new therapeutic approaches].
Stamatiou A; Herrera-Gómez RG; Szturz P; Bisig B; Romano E; Sykiotis G; Gorostidi F; La Rosa S; Kopp P; Cristina V
Rev Med Suisse; 2021 May; 17(739):962-966. PubMed ID: 34009754
[TBL] [Abstract][Full Text] [Related]
28. [Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer].
Altena R; Nilsson M; Bergman V; Dahlberg J; Christofer Juhlin C; Zedenius J
Lakartidningen; 2024 Feb; 121():. PubMed ID: 38712675
[TBL] [Abstract][Full Text] [Related]
29. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
30. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.
Choi YS; Kwon H; You MH; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Endocr Relat Cancer; 2022 May; 29(6):307-319. PubMed ID: 35343921
[TBL] [Abstract][Full Text] [Related]
31. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
32. Evaluating new treatments for anaplastic thyroid cancer.
Coca-Pelaz A; Rodrigo JP; Lopez F; Shah JP; Silver CE; Al Ghuzlan A; Menke-van der Houven van Oordt CW; Smallridge RC; Shaha AR; Angelos P; Mendenhall WM; Piazza C; Olsen KD; Corry J; Tufano RP; Sanabria A; Nuyts S; Nathan CA; Vander Poorten V; Dias FL; Suarez C; Saba NF; de Graaf P; Williams MD; Rinaldo A; Ferlito A
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1239-1247. PubMed ID: 36283091
[TBL] [Abstract][Full Text] [Related]
33. Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience.
Bueno F; Smulever A; Califano I; Guerra J; Del Grecco A; Carrera JM; Giglio R; Rizzo M; Lingua A; Voogd A; Negueruela MDC; Abelleira E; Pitoia F
Endocrine; 2023 Apr; 80(1):134-141. PubMed ID: 36617605
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in anaplastic thyroid cancer management.
Hamidi S; Maniakas A
Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):259-264. PubMed ID: 37410453
[TBL] [Abstract][Full Text] [Related]
35. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
Zeng Q; Deng Y; Zhang L; Wang W
Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
[TBL] [Abstract][Full Text] [Related]
36. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
37. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
38. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
39. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
40. Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis.
Song YS; Jung CK; Jung KC; Park YJ; Won JK
J Korean Med Sci; 2017 Oct; 32(10):1721-1726. PubMed ID: 28875621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
